Catchup News: HER2 ADC Special Report Part 1｜The Rise of Enhertu and Pharmacological Differentiation Driving the Second ADC Boom
Antibody-drug conjugates (ADCs) have emerged as one of the most exciting modalities in oncology. Among them, HER2-targeted ADCs have undergone a dramatic transformation with the arrival of Daiichi Sankyo and AstraZeneca’s Enhertu, sparki...
